Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Elixirgen Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner working in 1 distinct art unit. CHESTNUT, BARRY A is the busiest examiner for this portfolio, holding 1 pending office action. The concentration of the portfolio under this 1 distinct examiner suggests a focused prosecution effort for the company's current intellectual property.
Because the portfolio involves 1 distinct examiner and 1 distinct art unit, the company's success at the USPTO is currently tied to the interpretation of CHESTNUT, BARRY A. There is no opportunity to compare different examiner behaviors within the company's own data, as all activity is limited to this 1 distinct examiner. The 1 distinct art unit involved indicates that the technology being pursued fits within a specific technical group. Practitioners should focus on the specific history and preferences of CHESTNUT, BARRY A to navigate this prosecution path.
The Biotechnology & Pharmaceuticals technology area often involves complex biological systems, and having 1 pending office action suggests a controlled filing approach. This singular focus allows for a dedicated response to the examiner's concerns but lacks the broader context that a larger number of actions would provide. As the company continues its work, the prosecution landscape may change, but it currently remains centralized under 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18769203 | TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES | CHESTNUT, BARRY A | 1672 | §103DP | Non-Final OA | — | Pending | Jul 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElixirgen Therapeutics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Barry A Chestnut has the most, with 1 of Elixirgen Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
